Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Trovagene’s News Is Encouraging

April 24, 2019 0

About Trovagene Trovagene (TROV) is still a clinical-stage company. The precision cancer medicine approach is practicing what …

Novartis Gene Therapy Zolgensma Will Be Approved. The FDA Approves a Merck Combination for First-Line Renal cell Carcinoma. Regenxbio and Exelixis Are in Great Shape.

April 22, 2019 0

Zolgensma Findings The FDA submission of the gene therapy product Zolgensma was based on positive findings …

Novartis: More promising data from a Phase 3 trial with AveXis’ gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1

April 17, 2019 0

Novartis Has More Promising Data from Their Phase 3 Gene Therapy Trial with AveXis AveXis Inc., …

Gilead and insitro announce strategic collaboration to discover and develop novel therapies for NASH

April 16, 2019 0

Gilead and insitro Collaborate to Discover and Develop Novel Therapies for NASH using ISH Gilead Sciences …

The Week in Review #40

April 16, 2019 0

Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at …

$Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture$

Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture

April 10, 2019 0

Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (

Regeneron and Alnylam collaborative agreement will benefit these firms so why the selloff of both?

April 9, 2019 0

Regeneron and Alnylam Agreement Will Benefit Both So Why the Sell-Off? Regeneron Pharmacueticals Founded, and led …

The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals.

April 8, 2019 0

The Amgen/Novartis Story In May 2018 Amgen (AMGN) & Novartis (

Prohost Letter #430

April 5, 2019 0

Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary …

Sangamo’s stock price Soars 52% in pre-market hours on hemophilia A trial results

April 2, 2019 0

Sangamo’s Stock Price Soars Sangamo Therapeutics’ (SGMO) stock soared more than 52% in pre-market trading following …

Novartis’ Revolution: A new dimension and Prohost expectations

April 1, 2019 0

The Market is Outperforming Today. There is important news today about Novartis; part of which we …

Seattle Genetics: Why a selloff following good news

March 29, 2019 0

Following Seattle Genetics' (SGEN) and Astellas Pharma's announcement of positive results, from pivotal trial of the conjugated monoclonal antibody …

Why Agios Pharmaceuticals’ product TIBSOVO® was granted FDA Breakthrough Therapy designation. The FDA approves Jazz Pharmaceuticals’ product Sunosi

March 27, 2019 0

The uncontrolled blowing toxic wind contaminates this country’s environment, it brings down the oversold scientifically solid …

Aimmune Therapeutics’ product AR101 for the treatment of peanut allergy confirmed in Europe with previous successful results in the U.S.

March 26, 2019 0

While waiting for Mueller’s report we stopped speculating on the stocks in what we saw as …

Bluebird bio opens a state-of-the art gene and cell therapy manufacturing facility in Durham, NC

March 22, 2019 0

Governor Cooper to cut ribbon on bluebird bio facility Bluebird bio (BLUE) announced today, in its …

Biogen discontinued its Alzheimer’s disease drug Aducanumab. The usual selloff followed

March 21, 2019 0

Biogen’s (BIIB) decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE which is designed …

The FDA approves the first ever postpartum depression product. Positive results from Dermira’s atopic dermatitis product Lebrikizumab

March 20, 2019 0

News We Loved to Hear The First and Only Approval of a Specific Product for Postpartum …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Trovagene’s News Is Encouraging

Novartis Gene Therapy Zolgensma Will Be Approved. The FDA Approves a Merck Combination for First-Line Renal cell Carcinoma. Regenxbio and Exelixis Are in Great Shape.

Novartis: More promising data from a Phase 3 trial with AveXis’ gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1

Gilead and insitro announce strategic collaboration to discover and develop novel therapies for NASH

The Week in Review #40

Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture

Regeneron and Alnylam collaborative agreement will benefit these firms so why the selloff of both?

The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals.

Prohost Letter #430

Sangamo’s stock price Soars 52% in pre-market hours on hemophilia A trial results

Novartis’ Revolution: A new dimension and Prohost expectations

Seattle Genetics: Why a selloff following good news

Why Agios Pharmaceuticals’ product TIBSOVO® was granted FDA Breakthrough Therapy designation. The FDA approves Jazz Pharmaceuticals’ product Sunosi

Aimmune Therapeutics’ product AR101 for the treatment of peanut allergy confirmed in Europe with previous successful results in the U.S.

Bluebird bio opens a state-of-the art gene and cell therapy manufacturing facility in Durham, NC

Biogen discontinued its Alzheimer’s disease drug Aducanumab. The usual selloff followed

The FDA approves the first ever postpartum depression product. Positive results from Dermira’s atopic dermatitis product Lebrikizumab

During the Departed Week

End of the Year Decisions ~ Part 4

Atossa Genetics’ news that staged a huge Rally of this small firm’s stock